Solu Therapeutics Announces Presentation at ACS Industrial Mid-Career Investigator Award Symposium

Chief Technology Officer Brandon Turunen, PhD, honored, will give presentation on Solu’s CyTaC platform

BOSTON--(BUSINESS WIRE)--Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced that co-founder and CTO Brandon Turunen, PhD, will present at the American Chemical Society (ACS) Fall Meeting’s Industrial Mid-Career Investigator Award Symposium. At the Symposium, which honors non-academic researchers who have demonstrated sustained excellence in organic chemistry, Dr. Turunen will give a presentation highlighting Solu’s work to address cancer and immune-related diseases through the company’s proprietary CyTaC platform.

The details of the presentation are as follows:

Presentation Title: Applications of cytotoxicity targeting chimeras (CyTaCs) to unlock cellular surface targets to antibody pharmacology 
Location: Room 8, South Building, Moscone Center - 747 Howard St, San Francisco, CA 94103 
Time: August 15, 2023, 5:30-6:00pm PT

About Solu Therapeutics 
Solu Therapeutics, founded by Longwood Fund, is a precision-medicine company developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlocks antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.